Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Phase II planned for PTH (1-34) after merger

Jan. 17, 2005

Positive data for oral Rambazole in psoriasis

Jan. 14, 2005

CB-03-01: a novel, selective androgen antagonist for topical use

Jan. 13, 2005

Positive preclinical findings for Zeatin and cytokinin compounds

Jan. 11, 2005

Phase II AVAC study in childhood eczema fails to meet primary endpoint

Dec. 29, 2004

Bz-423, a novel benzodiazepine, suppresses cell growth in an in vitro psoriasis model

Dec. 28, 2004

Enrollment completed in phase III studies of Oracea

Dec. 27, 2004

RegeneRx seeks to begin new phase II study of TB4 for venous stasis ulcers

Dec. 23, 2004

Commercial launch for Evoclin

Dec. 15, 2004

ISA-247 investigated for psoriasis in Canadian phase III study

Dec. 9, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...